Access Vascular Announces New Bacterial Adhesion Data at INS 2024
May 21 2024 - 7:04AM
Business Wire
Data presented at the Infusion Nurses
Society Annual Scientific Meeting demonstrates limited bacterial
adhesion and thrombus accumulation with MIMIX™ material
Access Vascular, Inc. (AVI), a company addressing the most
common and costly vascular access complications with its advanced
biomaterial platform, today announced findings from new data
showing a reduction in bacterial adhesion and thrombus accumulation
in peripherally inserted central catheters (PICCs) and midline
catheters with AVI’s MIMIX® hydrophilic biomaterial (HBM) compared
with conventional catheters.
The new data, shared May 19 at the annual scientific meeting of
the Infusion Nurses Society in Kansas City, Mo., compared bacterial
adhesion on two polyurethane-based catheters with the HBM. The HBM
demonstrated a 99.999 percent reduction in bacterial adhesion
compared with both a standard polyurethane catheter and a
Chlorhexidine gluconate (CHG)-coated polyurethane material.1
“These results add to our compendium of MIMIX® evidence showing
lower rates of the most common and costly complications associated
with vascular access devices,” said James Biggins, founder and CEO
of Access Vascular. “We have now shown that our HBM-based catheters
significantly reduce bacterial adhesion, compared to all major
catheter materials currently available, and may be the key in the
fight against catheter-associated bloodstream infections.”
The study also demonstrated a 97 percent reduction in surface
thrombus accumulation for the HBM catheter material compared with
the CHG-coated polyurethane catheter, and 98 percent versus
standard polyurethane, echoing results shared in multiple prior
studies demonstrating the thromboresistance of HBM
catheters.2,3
“These new data reinforce my belief that this unique material
can have a substantial impact on reducing complications related to
vascular access, such as bloodstream infections,” said Lee Steere,
nurse manager for IV Therapy Services at Hartford Hospital in
Connecticut. “Our facility has logged zero catheter-related
bloodstream infections since we began using AVI’s HydroMID®
catheters in early 2023.”
Central-line associated bloodstream infections (CLABSI) can
increase hospital length of stay (LOS) by more than 17 days,
increase costs by more than $55,000 per admission, and pose a more
than 3.5-fold increased risk of mortality in ICU patients.4 A
single CLABSI case can cost a hospital more than in $1 million in
lost revenue, not including impacts on CMS reimbursement, and lead
to myriad patient complications.5,6 Rates of CLABSI infection have
risen as much as 51 percent since the COVID-19 pandemic.7
About Access Vascular
Access Vascular was founded to address the most common and
costly complications of intravenous therapy: infection, thrombosis,
and phlebitis. Taking a foundationally different approach to
thrombus reduction, the company manufactures intravenous catheters
from a proprietary hydrophilic material. Engineered to mimic the
body’s natural chemistry, Access Vascular catheters are designed to
evade the foreign body response and the complications that come
with it. Our award-winning, FDA-cleared products are HydroPICC® and
HydroMID®. For more information, please visit
www.accessvascularinc.com, and follow us on LinkedIn.
[1] Data collected using in vitro and static models. Data on
file at Access Vascular. Pre-clinical in vitro valuations do not
necessarily predict clinical performance with respect to thrombus
formation.
[2] Bunch J. A retrospective assessment of peripheral midline
failures focusing on catheter composition. J InfusNurs. Sept/Oct
2022; 45(5):270-27.
[3] Bunch J. A retrospective, comparative, clinical study of
occlusion rate of peripherally inserted central catheters
fabricated of poly(vinyl alcohol)-based hydrogel composite. J Mater
Sci Mater Med. 2023 Jul 21;34(7):34.
[4] Yu, C, et al. Characteristics, costs, and outcomes
associated with central-line–associated bloodstream infection and
hospital-onset bacteremia and fungemia in US hospitals. Infect.
Control Hosp. Epidemiol. 2023 July 44:12
[5] Shepard, J. Could the prevention of health care-associated
infections increase hospital cost? The financial impact of health
care-associated infections from a hospital management perspective.
J of Infection Control; 48 (2020) 255−260.
[6] Siempos II, Kopterides P, Tsangaris I, Dimopoulou I,
Armaganidis AE. Impact of catheter-related bloodstream infections
on the mortality of critically ill patients: a meta-analysis. Crit
Care Med 2009; 37:2283-9.
[7] Fakih, M., et al. (2021). Coronavirus disease 2019
(COVID-19) pandemic, central-line-associated bloodstream infection
(CLABSI), and catheter-associated urinary tract infection (CAUTI):
The urgent need to refocus on hardwiring prevention efforts.
Infection Control Hospital Epidemiology, 1-6.
Doi:10.1017/ice.2021.70
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521269547/en/
Brad Perriello Circle Hill Communications 617.817.1385
brad@circlehillcommunications.com